Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | <= 0.03 ug ml-1 | Tested in vitro for its antibacterial activity against vancomycin sensitive Enterococcus faecium (RLA1) | ChEMBL. | 11958977 |
MIC (functional) | = 0.06 ug ml-1 | Tested in vitro for its antibacterial activity against methicillin sensitive Staphylococcus aureus (MB2985) | ChEMBL. | 11958977 |
MIC (functional) | = 0.25 ug ml-1 | Compound was evaluated in vitro for its antibacterial activity against vancomycin intermediate resistant Staphylococcus aureus (CL5706) | ChEMBL. | 11958977 |
MIC (functional) | = 0.25 ug ml-1 | Tested in vitro for its antibacterial activity against vancomycin sensitive Enterococcus faecalis (MB2864) | ChEMBL. | 11958977 |
MIC (functional) | = 0.5 ug ml-1 | Compound was evaluated in vitro for its antibacterial activity against vancomycin intermediate resistant Staphylococcus aureus (CL5705) | ChEMBL. | 11958977 |
MIC (functional) | = 0.5 ug ml-1 | Tested in vitro for its antibacterial activity against vancomycin resistant Enterococcus faecium (MB5244) | ChEMBL. | 11958977 |
MIC (functional) | = 1 ug ml-1 | Tested in vitro for its antibacterial activity against methicillin resistant Staphylococcus aureus (COL) | ChEMBL. | 11958977 |
MIC (functional) | = 1 ug ml-1 | Tested in vitro for its antibacterial activity against methicillin resistant Staphylococcus aureus (MH76) | ChEMBL. | 11958977 |
MIC (functional) | = 2 ug ml-1 | Tested in vitro for its antibacterial activity against vancomycin resistant Enterococcus faecium (CL4931); 2-4 | ChEMBL. | 11958977 |
MIC (functional) | = 4 ug ml-1 | Tested in vitro for its antibacterial activity against vancomycin resistant Enterococcus faecalis (MB4877) | ChEMBL. | 11958977 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.